Neuralink Opens Global Patient Registry in Landmark Move Toward Worldwide Clinical Expansion

Neuralink, the neurotechnology company co-founded and led by Elon Musk—the world’s richest person, CEO of Tesla, and founder of xAI—announced on Wednesday local time that its patient registry platform is now open to all countries worldwide. This decision marks a milestone in Neuralink’s development, signifying that the scope of human trials for its brain-computer interface chip technology is expanding from the United States to the global stage at this very moment, andNeuralinkBrain-computer interface products, once officially approved, are expected to rapidly penetrate the global market.

The company announced the latest update via X, the social media platform led by Musk (formerly Twitter). In addition to leading Neuralink, Musk also serves as CEO of Tesla (TSLA.US), space exploration company SpaceX, and generative AI leader xAI.

Elon Musk stated earlier this week that the upgraded brain-computer interface chip “Blindsight,” developed by Neuralink, may be implanted in human patients for the first time by the end of 2025. In January, he revealed that 20 to 30 human patients would receive the newly upgraded version of Neuralink’s experimental brain-computer interface implant in 2025.

In January 2024, Neuralink completed the first human implantation of a brain-computer interface (BCI) chip. At that time, Neuralink implanted its BCI chip into the brain of its first human patient, marking a significant step toward the company’s goal of enabling humans to control computers with their minds. Neuralink’s first BCI chip product, named “Telepathy,” was described by Elon Musk as making it possible to “control your phone or computer, and virtually any device, just by thinking.”

Neuralink’s brain-computer interface technology consists of a wireless chip device implanted through the skull, directly connected to the brain via electrode wires. This rechargeable, innovative neurological hardware is designed to help patients with neurological disorders, such as limb paralysis and amyotrophic lateral sclerosis (ALS), control computers and other external electronic devices using only their thoughts.

Since receiving FDA approval in 2023 to initiate human-based brain-computer interface trials, Neuralink is currently conducting two critical clinical trials in human patients in the United States (PRIME and CONVOY) to evaluate its brain-computer interface chip and associated human neurotechnology. The company raised approximately $280 million in its Series D funding round in August 2023.

Neuralink is a neurotechnology company founded by Elon Musk, with the primary goal of developing implantable brain–machine interface (BMI) technology. This groundbreaking innovation aims to read and stimulate neural signals by implanting miniature BMI chips and electrodes into the human brain. It is designed to treat various neurological disorders, such as Parkinson’s disease and dementia, while also paving the way for seamless integration between the human brain and artificial intelligence, striving to create the “AI-enhanced humans” that Musk envisions in the near future.

Neuralink’s proprietary technologies include the use of highly advanced, flexible, high-density electrodes and an automated surgical implantation robot, which significantly reduces the complexity of the procedure. Over the past six to seven years, backed by hundreds of millions of dollars in investment, Neuralink has developed a comprehensive and leading R&D pipeline for implantable brain-computer interfaces (BCIs) worldwide, positioning itself at the international forefront. Compared with earlier technologies, Neuralink’s approach aims to deliver higher electrode density and a more precise, minimally invasive implantation process. Neuralink’s vision extends beyond medical applications, with the potential to enhance human cognitive capabilities, augment intellectual and physical capacities, and strive for the full integration of human consciousness with artificial intelligence.

Compared with technology companies like Blackrock Neurotech that focus on the brain-computer interface field, Neuralink’s technology places greater emphasis on high-density electrode networks and precision implantation techniques assisted by advanced robotics, aiming to achieve more detailed capture and control of brain activity. Although Neuralink started later than many of its peers, including Blackrock Neurotech, it has garnered significant attention from global media and the public, thanks to the resources and financial backing provided by Elon Musk, while also continuously securing investments in the venture capital sector.

Responsible Editor: Yu Jian SF069